Matrix metalloproteinase inhibitor development and the remodeling of drug discovery

Heart Failure Reviews

Volumn 9, Issue 1, 2004, Pages 63-79

  Peterson, J Thomas ^a  

^a PFIZER INC   (United States)

Author keywords

Attrition; Collagenase; Drug development; Drug discovery; Heart failure; Matrix metalloproteinase inhibitor; MMP

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; BATIMASTAT; BB 2983; CGS 27023A; CIPEMASTAT; COLLAGENASE; CP 471474; D 5410; DOXYCYCLINE HYCLATE; ENZYME INHIBITOR; GI 245402; GI 5402; ILOMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MM 270; MMI 270; NONSTEROID ANTIINFLAMMATORY AGENT; PD 0200126; PD 166793; PGE 7113313; PRINOMASTAT; REBIMASTAT; RS 11 3456; RS 13 0830; RS 132908; SOLIMASTAT; STROMMEX; TANOMASTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTHRALGIA; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COLLAGEN METABOLISM; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EDEMA; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME REGULATION; FIBROMYALGIA; FINANCIAL MANAGEMENT; HEART FAILURE; HEARTBURN; HUMAN; JOINT STIFFNESS; METABOLIC RATE; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; PERIODONTAL DISEASE; PROTEIN FAMILY; PROTEIN STABILITY; RASH; REVIEW; SKIN DISCOLORATION; SKINFOLD; TENDINITIS; TREATMENT FAILURE;

CARDIOMYOPATHY, DILATED; COLLAGEN; DOXYCYCLINE; DRUG DESIGN; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; MUSCULOSKELETAL DISEASES; MYOCARDIUM; NEOPLASMS; PERIODONTAL DISEASES;

EID: 1042263796     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:HREV.0000011395.11179.af     Document Type: Review

References (89)

1. Hodgson JA. Remodeling MMPIs. Biotechnology 1995;30:554-557.
2. Hauser P, Vaes G. Degradation of cartilage proteoglycans by a neutral proteinase secreted by rabbit bone-marrow macrophages in culture. Biochemical Journal 1978;172:275-284.
3. Lohi J, Wilson CL, Roby JD, Parks WC. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. Journal of Biological Chemistry 2001;276:10134-10144.
4. Nixon JS, Bottomley KMK, Broadhurst MJ, Brown PA, Johnson WH, Lawton G, Marley J, Sedgwick AD, Wilkinson SE. Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro. International Journal of Tissue Reactions 1991;13:237-243.
5. Baragi VM, Jordan H, Renkiewicz RR. A protocol for rapid screening of proteoglycan-degrading metalloproteinase inhibitors. Journal of Pharmacological & Toxicological Methods 1992;27:101-105.
6. Ye QZ, Johnson LL, Nordan I, Hupe D, Hupe L. A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors. Journal of Medicinal Chemistry 1994;37:206-209.
7. Ye QZ, Johnson LL, Hupe DJ, Baragi V. Purification and characterization of the human stromelysin catalytic domain expressed in Escherichia coli. Biochemistry 1992;31:11231-11235.
8. Moy FJ, Chanda PK, Chen J, Cosmi S, Edris W, Levin JI, Rush TS, Wilhelm J, Powers R. Impact of mobility on structure-based drug design for the MMPs. Journal of the American Chemical Society 2002;124:12658-12659.
9. Schwardt O, Kolb H, Ernst B. Drug discovery today. Current Topics in Medicinal Chemistry 2003;3:1-9.
10. Bohm HJ, G. S, eds. Protein-Ligand Interactions. From Molecular Recognition to Drug Design. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co KGaA, 2003.
11. Leach AR, Gillet VJ. An Introduction to Chemoinformatics. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2003.
12. Bleicher KH, Bohm HJ, Muller K, Alanine AI. Hit and lead generation: Beyond high-throughput screening. Nature Reviews. Drug Discovery 2003;2:369-378.
13. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 2002;3:928-944.
14. Norman P. The impact of new technologies on drug design. Drug News & Perspectives 2001;14:123-128.
15. Meador V, Jordan W, Zimmermann J. Increasing throughput in lead optimization in vivo toxicity screens. Current Opinion in Drug Discovery & Development 2002;5:72-78.
16. Colburn WA. Biomarkers in drug discovery and development: From target identification through drug marketing. Journal of Clinical Pharmacology 2003;43:329-341.
17. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nature Reviews. Drug Discovery 2003;2:566-580.
18. Rosenkranz B. Biomarkers and surrogate endpoints in clinical drug development. Applied Clinical Trials 2003;12:30-40.
19. kaisernetwork.org. Prescription Drugs Cost of New Drug Development Reaches $897M. In, 2003.
20. Workman RW. Simulation of the drug development process: A case study from the pharmaceutical industry. In: Anderson Consulting, 2001.
21. Nguyen Q, Willenbrock F, Cockett MI, O'Shea M, Docherty AJ, Murphy G. Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A. Biochemistry 1994;33:2089-2095.
22. Stratmann B, Farr M, Tschesche H. Characterization of C-terminally truncated human tissue inhibitor of metalloproteinases-4 expressed in Pichia pastoris. Biological Chemistry 2001;382:987-991.
23. Baragi VM, Fliszar CJ, Conroy MC, Ye QZ, Shipley JM, Welgus HG. Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrilysin exhibit equally compromised binding affinities as compared to full-length stromelysin. Journal of Biological Chemistry 1994;269:12692-12697.
24. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. European Journal of Cell Biology 1997;74:111-122.
25. Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, Denhardt DT. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 1989;243:947-950.
26. Colandrea TD, D'Armiento J, Kesari KV, Chada KK. Collagenase induction promotes mouse tumorigenesis by two independent pathways. Molecular Carcinogenesis 2000;29:8-16.
27. Sternlicht MD, Bissell MJ, Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 2000;19:1102-1113.
28. Neuhold LA, Killar L, Zhao W, Sung ML, Warner L, Kulik J, Turner J, Wu W, Billinghurst C, Meijers T, Poole AR, Babij P, DeGennaro LJ. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. Journal of Clinical Investigation 2001;107:35-44 (comment).
29. Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, Defreyte G, Soloway PJ, Zile MR, Spinale FGIZMR. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. Journal of Molecular & Cellular Cardiology 2000;32:109-120.
30. Creemers EE, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, Hauet AM, Escobar PG, Cleutjens JP, Smits JF, Daemen MJ, Zile MR, Spinale FG. Deficiency of TIMP-1 exacerbates IV remodeling after myocardial infarction in mice. American Journal of Physiology - Heart & Circulatory Physiology 2003;284:H364-371.
31. Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. Journal of Clinical Investigation 2000;106:857-866 (comment).
32. DeClerck YA, Imren S. Protease inhibitors: Role and potential therapeutic use in human cancer. European Journal of Cancer 1994;30A:2170-2180.
33. Kruger A, Sanchez-Sweatman OH, Martin DC, Fata JE, Ho AT, Orr FW, Ruther U, Ehokha R. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 1998;16:2419-2423.
34. Buck TB, Yoshiji H, Harris SR, Bunce OR, Thorgeirsson UP. The effects of sustained elevated levels of circulating tissue inhibitor of metalloproteinases-1 on the development of breast cancer in mice. Annals of the New York Academy of Sciences 1999;878:732-735.
35. Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Masaki T, Fukui H. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. International Journal of Cancer 2003;105:340-346.
36. Schett G, Hayer S, Tohidast-Akrad M, Schmid BJ, Lang S, Turk B, Kainberger F, Haralambous S, Kollias G, Newby AC, Xu Q, Steiner G, Smolen J. Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. Arthritis & Rheumatism 2001;44:2888-2898.
37. Schultz RM, Silberman S, Persky B, Bajkowski AS, Carmichael DF. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Research 1988;48:5539-5545.
38. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Medicine 1999;5:1135-1142 (comment).
39. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-490.
40. Clark IM, Powell LK, Cawston TE. Tissue inhibitor of metalloproteinases (TIMP-1) stimulates the secretion of collagenase from human skin fibroblasts. Biochemical & Biophysical Research Communications 1994;203:874-880.
41. Greenwald RA. Thirty-six years in the clinic without an MMP inhibitor. What hath collagenase wrought? Annals of the New York Academy of Sciences 1999;878:413-419.
42. Rosemurgy A, Harris J, Langleben A, Casper E, Goode S, Rasmussen H. Marimastat in patients with advanced pancreatic cancer: A dose-finding study. American Journal of Clinical Oncology 1999;22:247-252.
43. Tierney GM, Griffin NR, Stuart RC, Kasem H, Lynch KP, Lury JT, Brown PD, Millar AW, Steele RJ, Parsons SL. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. European Journal of Cancer 1999;35:563-568.
44. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clinical Cancer Research 1998;4:1101-1109.
45. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. Journal of Clinical Oncology 1998;16:2150-2156.
46. Boasberg P, Eisenberg M, Harris J, Langleben A, Ahmann F, Roth B, Berkheimer M, Rasmussen H. Marimastat in patients with hormone refractory prostate concer: A dose-finding study. Proc Am Soc Clin Oncol 1997;16:316A.
47. Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJ, Huxley P, Laber D, McCourt M, Whittaker M, Wood LM, Wright A. Preclinical and clinical studies of MMP inhibitors in cancer. Annals of the New York Academy of Sciences 1999;878:228-235.
48. Hutchinson JW, Tierney GM, Parsons SL, Davis TR. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. Journal of Bone & Joint Surgery - British Volume 1998;80:907-908.
49. King J, Zhao J, Clingan P, Morris D. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: Significant survival advantage in patients with musculoskeletal side-effects. Anticancer Research 2003;23:639-645.
50. Whittaker M, Floyd CD, Brown P, Gearing AJH. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999;99:2735-2776.
51. Bird J, Montana G, Wills RE, Baxter AD, Owens DA. Chem Abstr 1998;129:22571.
52. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opinion on Investigational Drugs 2000;9:2167-2177.
53. Renkiewicz R, Qiu L, Lesch C, Sun X, Devalaraja R, Cody T, Kaldjian E, Welgus H, V. B. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis and Rheumatism 2003;48:1742-1749.
54. Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, Sheth KV, Eid WA, Dowling O, Harris J, Glucksman MJ, Bahabri S, Meyer BF, Desnick RJ. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nature Genetics 2001;28:261-265 (comment).
55. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998;93:411-422.
56. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999;99:81-92.
57. Gomis-Ruth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov GP, Bartunik H, Bode W. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997;389:77-81.
58. Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, Tschesche H, Maskos K. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO Journal 1998;17:5238-6248.
59. van der Laan WH, Quax PH, Seemayer CA, Huisman LG, Pieterman EJ, Grimbergen JM, Verheijen JH, Breedveld FC, Gay RE, Gay S, Huizinga TW, Pap T. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Therapy 2003;10:234-242.
60. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-812.
61. Gore M, A'Hern R, Stankiewicz M, Slevin M. Tumour marker levels during marimastat therapy. Lancet 1996;348:263-264 (comment).
62. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. Journal of the National Cancer Institute 2001;93:178-193.
63. Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS malignancy consortium study. Journal of Clinical Oncology 2002;20:153-159.
64. Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, Leco K, Chamberlain D, Shepherd FA. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. Journal of Clinical Oncology 1999;17:1802-1808.
65. Corporation B. In, 1999.
66. Moore M, et al. Proc Am Soc Clin Oncol 2001;19:240a.
67. Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proceedings of the National Academy of Sciences of the United States of America 2000;97:2202-2207.
68. Pozzi A, LeVine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002;21:272-281.
69. Golub LM, Ciancio S, Ramamamurthy NS, Leung M, McNamara TF. Low-dose doxycycline therapy: Effect on gingival and crevicular fluid collagenase activity in humans. Journal of Periodontal Research 1990;25:321-330.
70. Kiili M, Cox SW, Chen HW, Wahlgren J, Maisi P, Eley BM, Salo T, Sorsa T. Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: Molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. Journal of Clinical Periodontology 2002;29:224-232.
71. Caton J, Blieden T, Adams D, al. e. Subantimicrobial doxycycline therapy for periodontitis. J Dent Res 1997;76.
72. Caton J, Ciancio S, Crout R, Hefti A, Polson A. Adjunctive use of subantimicrobial doxycycline therapy for periodontitis. J Dent Res 1998;77:1001.
73. Caton JG, Ciancio SG, Blieden TM, Bradshaw M, Crout RJ, Hefti AF, Massaro JM, Polson AM, Thomas J, Walker C. Subantimicrobial dose doxycycline as an adjunct to scaling and root planing: Post-treatment effects. Journal of Clinical Periodontology 2001;28:782-789.
74. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW, Jr., Kent KC, Upchurch GR, Jr., Chaikof EL, Mills JL, Fleckten B, Longo GM, Lee JK, Thompson RW. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: Report of a prospective (Phase II) multicenter study. Journal of Vascular Surgery 2002;36:1-12.
75. Bachmann LH, Stephens J, Richey CM, Hook EW, 3rd. Measured versus self-reported compliance with doxycyeline therapy for chlamydia-associated syndromes: High therapeutic success rates despite poor compliance. Sexually Transmitted Diseases 1999;26:272-278 (comment).
76. Pharmaceuticals C. CGPI fact sheet 8-13-02. In, 2002.
77. Baker PJ, Evans RT, Coburn RA, Genco RJ. Tetracycline and its derivatives strongly bind to and are released from the tooth surface in active form. Journal of Periodontology 1983;54:580-585.
78. Loesche WJ. Periodontal disease as a risk factor for heart disease. Compendium 1994;15:976, 978-982, 985-986 passim; quiz 992.
79. Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S. Periodontal disease and cardiovascular disease. Journal of Periodontology 1996;67:1123-1137.
80. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. Journal of Periodontology 2000;71:1554-1560.
81. Gibson FC, Hong C, Wang J, Genco C. Oral infection with invasive P gingivalis stimulates accelerated atherosclerotic plaque formation in ApoE Mice. Interscience Conference on Antimicrobial Agents, San Diego, 2002.
82. Genco RJ, Glurich I, Haraszthy VI. Overview of risk factors for periodontal disease and implications for diabetes and cardiovascular disease. Compendium of Continuing Education in Dentistry 1998;Suppl S40-46.
83. Franklin IJ, Harley SL, Greenhalgh RM, Powell JT. Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis. British Journal of Surgery 1999;86:771-775.
84. Lokeshwar BL. MMP inhibition in prostate cancer. Annals of the New York Academy of Sciences 1999;878:271-289.
85. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Annals of the New York Academy of Sciences 1999;878:159-178.
86. French BA, Mazur W, Geske RS, Bolli R. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation 1994;90:2414-2424.
87. Gilgenkrantz H, Duboc D, Juillard V, Couton D, Pavirani A, Guillet JG, Briand P, Kahn A. Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: Role of the immune response. Human Gene Therapy 1995;6:1265-1274.
88. Steiner G. The use of fibrates and of statins in preventing atherosclerosis in diabetes. Current Opinion in Lipidology 2001;12:611-617.
89. King MK, Coker ML, Goldberg A, McElmurray JH, 3rd, Gunasinghe HR, Mukherjee R, Zile MR, O'Neill TP, Spinale FG. Selective matrix metalloproteinase inhibition with developing heart failure: Effects on left ventricular function and structure. Circulation Research 2003;92:177-185.